KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: BIOLOGICAL: KN035|BIOLOGICAL: Trastuzumab|DRUG: Docetaxel
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University